These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 38276064)

  • 1. Cardiopulmonary Events of the Elderly (≥75 Years) during Clazosentan Therapy after Subarachnoid Hemorrhage: A Retrospective Study from a Tertiary Stroke Center in Japan.
    Mutoh T; Aono H; Seto W; Kimoto T; Tochinai R; Moroi J; Ishikawa T
    Medicina (Kaunas); 2024 Jan; 60(1):. PubMed ID: 38276064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors Influencing Discontinuation of Clazosentan Therapy in Elderly Patients with Aneurysmal Subarachnoid Hemorrhage: A Retrospective Study from a Japanese Single Center.
    Mutoh T; Aono H; Seto W; Kimoto T; Tochinai R; Moroi J; Ishikawa T
    Med Sci Monit; 2024 Feb; 30():e943303. PubMed ID: 38361355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thick and Diffuse Subarachnoid Blood as a Treatment Effect Modifier of Clazosentan After Subarachnoid Hemorrhage.
    Mayer SA; Aldrich EF; Bruder N; Hmissi A; Macdonald RL; Viarasilpa T; Marr A; Roux S; Higashida RT
    Stroke; 2019 Oct; 50(10):2738-2744. PubMed ID: 31394993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dissociation of vasospasm-related morbidity and outcomes in patients with aneurysmal subarachnoid hemorrhage treated with clazosentan: a meta-analysis of randomized controlled trials.
    Shen J; Pan JW; Fan ZX; Xiong XX; Zhan RY
    J Neurosurg; 2013 Jul; 119(1):180-9. PubMed ID: 23641823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preventive Effect of Clazosentan against Cerebral Vasospasm after Clipping Surgery for Aneurysmal Subarachnoid Hemorrhage in Japanese and Korean Patients.
    Fujimura M; Joo JY; Kim JS; Hatta M; Yokoyama Y; Tominaga T
    Cerebrovasc Dis; 2017; 44(1-2):59-67. PubMed ID: 28463833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled, multicenter phase IIa study.
    Vajkoczy P; Meyer B; Weidauer S; Raabe A; Thome C; Ringel F; Breu V; Schmiedek P
    J Neurosurg; 2005 Jul; 103(1):9-17. PubMed ID: 16121967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): randomized, double-blind, placebo-controlled phase 2 dose-finding trial.
    Macdonald RL; Kassell NF; Mayer S; Ruefenacht D; Schmiedek P; Weidauer S; Frey A; Roux S; Pasqualin A;
    Stroke; 2008 Nov; 39(11):3015-21. PubMed ID: 18688013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clazosentan for Improvement of Time to Peak Perfusion in Patients with Angiographically Confirmed Severe Vasospasm.
    Lai A; Tan CO; Vranic J; Weidauer S; Leslie-Mazwi T; Hirsch JA; Gupta R
    Neurocrit Care; 2022 Feb; 36(1):240-247. PubMed ID: 34296399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Update on the Efficacy and Safety Profile of Clazosentan in Cerebral Vasospasm After Aneurysmal Subarachnoid Hemorrhage: A Meta-Analysis.
    Song J; Xue YQ; Wang YJ; Xu P; Sun DK; Chen W
    World Neurosurg; 2019 Mar; 123():e235-e244. PubMed ID: 30496924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of efficacy between clazosentan and fasudil hydrochloride-based management of vasospasm after subarachnoid hemorrhage focusing on older and WFNS grade V patients: a single-center experience in Japan.
    Mochizuki T; Ryu B; Shima S; Kamijyo E; Ito K; Ando T; Kushi K; Sato S; Inoue T; Kawashima A; Kawamata T; Okada Y; Niimi Y
    Neurosurg Rev; 2024 Mar; 47(1):113. PubMed ID: 38472507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomised trial of clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid hemorrhage undergoing surgical clipping (CONSCIOUS-2).
    Macdonald RL; Higashida RT; Keller E; Mayer SA; Molyneux A; Raabe A; Vajkoczy P; Wanke I; Bach D; Frey A; Marr A; Roux S; Kassell N
    Acta Neurochir Suppl; 2013; 115():27-31. PubMed ID: 22890639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized trial of clazosentan in patients with aneurysmal subarachnoid hemorrhage undergoing endovascular coiling.
    Macdonald RL; Higashida RT; Keller E; Mayer SA; Molyneux A; Raabe A; Vajkoczy P; Wanke I; Bach D; Frey A; Nowbakht P; Roux S; Kassell N
    Stroke; 2012 Jun; 43(6):1463-9. PubMed ID: 22403047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2).
    Macdonald RL; Higashida RT; Keller E; Mayer SA; Molyneux A; Raabe A; Vajkoczy P; Wanke I; Bach D; Frey A; Marr A; Roux S; Kassell N
    Lancet Neurol; 2011 Jul; 10(7):618-25. PubMed ID: 21640651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clazosentan for Aneurysmal Subarachnoid Hemorrhage: An Updated Meta-Analysis with Trial Sequential Analysis.
    Cho SS; Kim SE; Kim HC; Kim WJ; Jeon JP
    World Neurosurg; 2019 Mar; 123():418-424.e3. PubMed ID: 30508597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different effects of clazosentan on consequences of subarachnoid hemorrhage in rats.
    Chen G; Tariq A; Ai J; Sabri M; Jeon HJ; Tang EJ; Lakovic K; Wan H; Macdonald RL
    Brain Res; 2011 May; 1392():132-9. PubMed ID: 21466789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clazosentan, an endothelin receptor antagonist, prevents early hypoperfusion during the acute phase of massive experimental subarachnoid hemorrhage: a laser Doppler flowmetry study in rats.
    Schubert GA; Schilling L; Thomé C
    J Neurosurg; 2008 Dec; 109(6):1134-40. PubMed ID: 19035733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversal of Vasospasm with Clazosentan After Aneurysmal Subarachnoid Hemorrhage: A Pilot Study.
    Higashida RT; Bruder N; Gupta R; Guzman R; Hmissi A; Marr A; Mayer SA; Roux S; Weidauer S; Aldrich EF
    World Neurosurg; 2019 Aug; 128():e639-e648. PubMed ID: 31054336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of the selective endothelin A (ET(A)) receptor antagonist Clazosentan on cerebral perfusion and cerebral oxygenation following severe subarachnoid hemorrhage - preliminary results from a randomized clinical series.
    Barth M; Capelle HH; Münch E; Thomé C; Fiedler F; Schmiedek P; Vajkoczy P
    Acta Neurochir (Wien); 2007; 149(9):911-8; discussion 918. PubMed ID: 17700991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of clazosentan in patients with aneurysmal subarachnoid hemorrhage: a meta-analysis of randomized controlled trials.
    Wang X; Li YM; Li WQ; Huang CG; Lu YC; Hou LJ
    PLoS One; 2012; 7(10):e47778. PubMed ID: 23082215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clazosentan: prevention of cerebral vasospasm and the potential to overcome infarction.
    Beck J; Raabe A
    Acta Neurochir Suppl; 2011; 110(Pt 2):147-50. PubMed ID: 21125461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.